Market Overview:
The global snake antivenom market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of snakebites, rising demand for effective and safe snake antivenoms, and growing awareness about available treatments for venomous bites. The global snake antivenom market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into human-derived and animal-derived products. The human-derived products are further subsegmented into monovalent and polyvalent products. On the basis of application, the market is divided into two segments: application I (envenomation by venomous snakes that are endemic in a particular geographical area) and application II (envenomation by venomous snakes that are not endemic in a particular geographical area). Geographically, this market has been segmented into five regions: North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
Snake Antivenom is an injection used to treat venomous snakebites. It is made from the blood of horses that have been vaccinated against snake venom.
Humans:
Snakes are immune to the human disease and cannot pass on the infection. The only way a snake can transmit the infection is by bites or stings. However, in some cases, people do get infected due to unhygienic conditions or contact with contaminated clothing. In such cases, antivenom is used for treatment of envenoming/bites from poisonous snakes/snake bite and neutralization of their toxins.
Animals:
Snakes are immune system of the nature and they have antibodies for the protection against different diseases. The snake venom has evolved as a drug to fight against various diseases. Various types of snakes have been known to possess medicinal properties, which help them fight off infections and other microbial agents.
The most widely used type of snake in medicine is the rattlesnake (Crotalinae).
Application Insights:
Application I was the largest segment in terms of revenue and accounted for 69.3% share of the global revenue in 2017. This is attributed to increasing number of snakebites worldwide, especially in rural areas where access to advanced healthcare facilities is limited. According to a study published by WHO, it was estimated that globally around 1 million people are bitten by snakes every year and around 150,000 die due to these bites.
Regional Analysis:
North America dominated the global snake antivenom market in 2017, with a revenue share of around 42.0%. The presence of advanced healthcare infrastructure and high incidence rate of envenoming incidents are some factors responsible for the largest revenue share. Moreover, increasing number of people traveling to North American countries such as U.S., Canada, and Mexico for recreational purposes is anticipated to drive demand for snakebite treatment in this region over the forecast period.
Asia Pacific is expected to witness lucrative growth over the coming years owing to rising incidence rates due to bites from venomous snakes across various countries such as India, Australia, Indonesia etc.; thus promoting demand for these products during medical emergencies involving risk of death if untreated or improperly treated (examples: severe allergic reactions or anaphylaxis). Furthermore; increasing awareness about first aid treatment options among common public will also boost regional market growth during the forecast period.
Growth Factors:
- Increasing snake bite incidents in the developing countries: The major growth driver for the snake antivenom market is the increasing number of snake bite incidents in the developing countries. As per a study by World Health Organization (WHO), it is estimated that around 5.4 million people are bitten by snakes every year, out of which 2.7 million require treatment and around 100,000 die due to snake bites annually. This high number of fatalities due to snake bites is mainly because most of these cases occur in rural areas where access to medical care is limited and also because most traditional treatments available are not very effective against venomous snakes. Thus, there is a huge unmet need for an effective and affordable antivenom therapy which can save lives of millions of people every year.
- Growing awareness about Snake Antivenom: Another key growth driver for this market is the growing awareness about Snake Antivenom among people living in endemic areas as well as healthcare professionals working in these regions. With increased education and awareness programs on venomous snakes and their management, more people are now aware about the need for an effective antivenom therapy during a potential snakebite emergency situation .This has led to an increase in demand for Snake Antivenoms globally over past few years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Snake Antivenom Market Research Report
By Type
Humans, Animals
By Application
Application I, Application II
By Companies
Merck, Summerland Serums (AU), Haffkine Bio Pharmaceutical, MicroPharm, CSL (AU), SAVP, Flynn Pharma, Serum
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Snake Antivenom Market Report Segments:
The global Snake Antivenom market is segmented on the basis of:
Types
Humans, Animals
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Application I, Application II
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Summerland Serums (AU)
- Haffkine Bio Pharmaceutical
- MicroPharm
- CSL (AU)
- SAVP
- Flynn Pharma
- Serum
Highlights of The Snake Antivenom Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Humans
- Animals
- By Application:
- Application I
- Application II
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Snake Antivenom Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Snake antivenom is a serum that neutralizes the venom of some snakes.
Some of the key players operating in the snake antivenom market are Merck, Summerland Serums (AU), Haffkine Bio Pharmaceutical, MicroPharm, CSL (AU), SAVP, Flynn Pharma, Serum.
The snake antivenom market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Snake Antivenom Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Snake Antivenom Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Snake Antivenom Market - Supply Chain
4.5. Global Snake Antivenom Market Forecast
4.5.1. Snake Antivenom Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Snake Antivenom Market Size (000 Units) and Y-o-Y Growth
4.5.3. Snake Antivenom Market Absolute $ Opportunity
5. Global Snake Antivenom Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Snake Antivenom Market Size and Volume Forecast by Type
5.3.1. Humans
5.3.2. Animals
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Snake Antivenom Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Snake Antivenom Market Size and Volume Forecast by Application
6.3.1. Application I
6.3.2. Application II
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Snake Antivenom Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Snake Antivenom Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Snake Antivenom Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Snake Antivenom Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Snake Antivenom Demand Share Forecast, 2019-2026
9. North America Snake Antivenom Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Snake Antivenom Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Snake Antivenom Market Size and Volume Forecast by Application
9.4.1. Application I
9.4.2. Application II
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Snake Antivenom Market Size and Volume Forecast by Type
9.7.1. Humans
9.7.2. Animals
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Snake Antivenom Demand Share Forecast, 2019-2026
10. Latin America Snake Antivenom Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Snake Antivenom Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Snake Antivenom Market Size and Volume Forecast by Application
10.4.1. Application I
10.4.2. Application II
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Snake Antivenom Market Size and Volume Forecast by Type
10.7.1. Humans
10.7.2. Animals
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Snake Antivenom Demand Share Forecast, 2019-2026
11. Europe Snake Antivenom Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Snake Antivenom Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Snake Antivenom Market Size and Volume Forecast by Application
11.4.1. Application I
11.4.2. Application II
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Snake Antivenom Market Size and Volume Forecast by Type
11.7.1. Humans
11.7.2. Animals
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country 11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Snake Antivenom Demand Share, 2019-2026
12. Asia Pacific Snake Antivenom Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Snake Antivenom Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Snake Antivenom Market Size and Volume Forecast by Application
12.4.1. Application I
12.4.2. Application II
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Snake Antivenom Market Size and Volume Forecast by Type
12.7.1. Humans
12.7.2. Animals
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Snake Antivenom Demand Share, 2019-2026
13. Middle East & Africa Snake Antivenom Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Snake Antivenom Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Snake Antivenom Market Size and Volume Forecast by Application
13.4.1. Application I
13.4.2. Application II
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Snake Antivenom Market Size and Volume Forecast by Type
13.7.1. Humans
13.7.2. Animals
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Snake Antivenom Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Snake Antivenom Market: Market Share Analysis
14.2. Snake Antivenom Distributors and Customers
14.3. Snake Antivenom Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Summerland Serums (AU)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Haffkine Bio Pharmaceutical
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. MicroPharm
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. CSL (AU)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. SAVP
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Flynn Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Serum
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
